Why the study?
Acute coronary artery occlusion is a relatively rare procedural adverse event in valve-in-valve transcatheter aortic valve implantation.
Case Report (n=1)
Intravenous antithrombotic and anticoagulant therapy can serve as a successful bailout strategy for coronary occlusion during valve-in-valve TAVI when catheter engagement is impossible.
Answers are grounded in this paper and cite their sources.
Coronary occlusion remains a risk in valve-in-valve TAVI; extends limited case evidence for upfront protection but leaves open systematic validation.
Acute coronary artery occlusion is a relatively rare procedural adverse event in valve-in-valve transcatheter aortic valve implantation. Here we present a case of a 26-mm Sapien 3 prosthetic valve implantation in a degenerated 23-mm Freedom Solo bioprosthetic surgical valve with subsequent left and right coronary occlusion. Left coronary artery occlusion was managed immediately with the use of an upfront coronary artery protection technique and drug-eluting stent placement. Right coronary artery occlusion presented with right-sided heart failure and cardiac arrest that required resuscitation and additional hemodynamic support. As the artery could not be engaged with a catheter, a combination of intravenous antithrombotic and anticoagulant therapy was used as a successful bailout step to restore adequate coronary flow.
No takes yet. Share an insight, caveat, or question.
Bunc et al. (2022) conducted a case report in Degenerated surgical bioprosthetic aortic valve (n=1). Valve-in-valve TAVI with chimney technique and bailout antithrombotic therapy was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: